Table 2 The most frequent (%) non-beta-lactam co-resistance patterns of Staphylococcus aureus isolates at IKHC, Tehran, Iran, 2018–2019
MSSA | MRSA | Overall |
|---|---|---|
CLI/ERY (33.6) | CLI/ERY (84.6) | CLI/ERY (53.0) |
DOX/TET (29.8) | CIP/ERY (77.7) | CIP/LVX (50.9) |
CIP/ERY/LVX (27.5) | CIP/CLI (75.5) | CIP/CLI/ERY/LVX (49.5) |
CIP/CLI/ERY/LVX/SXT (26.7) | CIP/CLI/ERY (75.3) | CIP/CLI/LVX (49.1) |
CIP/CLI/LVX (26.5) | CIP/LVX (71.2) | CIP/ERY (44.9) |
CIP/CLI/ERY/LVX (26.1) | CIP/CLI/ERY/LVX (67.8) | CIP/CLI (43.7) |
ERY/TET (26.1) | ERY/GEN (60.6) | CIP/CLI/ERY (43.0) |
CIP/DOX (26.0) | CIP/GEN (59.2) | CLI/TET (41.2) |
CLI/TET (25.5) | CLI/ERY/GEN (59.2) | ERY/TET (40.6) |
CIP/CLI/LVX/SXT CIP/ERY/LVX/SXT (25.5) | CIP/ERY/GEN (58.8) | CIP/LVX/TET (40.4) |